Benefits
Amino acid and protein absorption enhancement
In a 30 person randomized crossover pilot, 50 mg of AstraGin twice daily for 4 weeks raised the plasma area under the curve after a 25 g whey protein drink by 14.07% for valine and 8.34% for leucine versus placebo (both p < 0.05); isoleucine rose 6.33% without reaching significance. The acute test found no significant change at all: valine 6.67%, leucine 3.62%, isoleucine 0.15%, and the paper states the differences were not significant. Grip strength rose in both arms over the 4 weeks (AstraGin +5.20%, placebo +2.44%) and the paper reports only a main effect of time (p = 0.002), not a significant difference between AstraGin and placebo; the muscle mass difference (+0.85% versus +0.68%) is too small to mean anything. The transporter explanation (carriers in the gut lining that move sugars and amino acids) comes from intestinal cell culture and animal work; transporter expression was not measured in these participants.
Absorption of other nutrients: cell and animal data only
The list of nutrients AstraGin is said to help absorb (L-citrulline, creatine, folate, glucosamine, curcumin, B vitamins, vitamins C and D, omega-3 fatty acids) rests on intestinal cell culture and rodent studies, not on trials in people. Only two co-ingested nutrients have been measured in humans. Amino acids from whey protein, covered above. And L-arginine: in an acute crossover test, 50 mg taken the evening before and 50 mg taken with 5 g of arginine raised the arginine blood curve by 17.3% (p = 0.041) and the arginine to ADMA ratio by 167% (p = 0.007) in 24 analysed subjects, although 6 of the 30 were dropped from that analysis after the fact for large individual variation, which weakens the result. Nothing published shows AstraGin raising blood levels of creatine, curcumin or any vitamin in a human being, and the only functional outcomes anyone has measured, grip strength and muscle mass, showed no significant difference from placebo.
Gut barrier and microbiome: one 8 person pilot in ulcerative colitis
The gut data come from a pilot trial in people with moderate ulcerative colitis, not from healthy supplement users. Fourteen were screened, 9 enrolled and 8 analysed, aged 25 to 70: 5 on AstraGin, 3 on placebo. Over 3 months at 50 mg twice daily, the AstraGin group's own baseline to 3 month figures moved: fecal calprotectin fell 60.9% (p = 0.015), the lactulose to mannitol ratio fell about 40% (p = 0.02) and myeloperoxidase activity fell 58% (p = 0.046). In the placebo group calprotectin fell 10.9% and myeloperoxidase 7.0%, neither significant. Those p values compare each group with its own baseline, not AstraGin against placebo, so they do not establish that the two groups differed. The often quoted 420% rise in Faecalibacterium prausnitzii and 181% rise in Bifidobacterium adolescentis were reported as raw percentage changes with no statistical test attached, and the changes in alpha diversity, IL-6, IL-17A and IL-10 were not significant. In healthy adults, the separate 4-week trial found no significant change in blood zonulin (treatment p = 0.174). Eight people is too few to conclude anything, and a result in an inflammatory bowel condition does not transfer to a healthy reader.
Mechanism of action
Intestinal transporter upregulation and tight junction support
This is a cell culture and animal mechanism, not something measured in the people who took AstraGin. In Caco-2 intestinal cell monolayers, ginsenosides raise expression of the sodium-glucose cotransporter SGLT1 and astragalosides act on cationic amino acid (CAT) transporters, and the supplier's US patent claims this effect for glucose, arginine, tryptophan and folate uptake across intestinal cells. Tight junction proteins (ZO-1 and occludin) are reported to increase in the same models. No human study has measured transporter or tight junction expression after taking AstraGin, so treat this as a proposed explanation for the amino acid absorption results rather than as a demonstrated pathway.
Clinical trials
Randomized, double-blind, placebo-controlled crossover pilot (NCT06110260) of AstraGin (50 mg capsules of standardized Astragalus membranaceus and Panax notoginseng saponin extract) on whey protein amino acid absorption in 30 healthy adults, 10 in each of three age bands (18-25, 26-59, 60-80 years). Two phases: an acute test (one capsule the night before, one with 25 g whey protein) with 8 post-meal blood draws over 180 minutes, then 4 weeks of 50 mg twice daily with home-based resistance training, with a 4-week washout between arms. Published in Nutrients 2026;18(3):504, PMID 41683325. Funded by Chung Shan Medical University; the AstraGin and placebo capsules were donated by NuLiv Science, which sells the ingredient. No independent group has repeated it.
30 healthy adults, 10 aged 18-25, 10 aged 26-59 and 10 aged 60-80, each taking both AstraGin and placebo, with a 4-week washout between arms.
The acute test produced no significant change: valine AUC +6.67%, leucine +3.62%, isoleucine +0.15% versus placebo, and the paper states the differences were not significant. After 4 weeks the difference reached significance for two amino acids: valine AUC +14.07% and leucine +8.34% (both p < 0.05); isoleucine +6.33% did not. Arginine AUC rose 5.05%, with no significance test reported. Participants aged 60-80 showed a 12.74% higher total essential amino acid AUC. Grip strength improved in both arms over the 4 weeks (AstraGin +5.20%, placebo +2.44%), with only a main effect of time reported (p = 0.002) and no significant treatment effect; muscle mass changed +0.85% versus +0.68%. Blood zonulin fell 13.01% on AstraGin versus 0.90% on placebo, but this was not statistically significant (treatment p = 0.174, time p = 0.498, interaction p = 0.552). Creatinine, AST and ALT were unchanged; blood urea nitrogen rose significantly in both arms but stayed inside the normal range, and no adverse effects were reported. The authors call it a pilot study.
Randomized, double-blind, placebo-controlled parallel pilot in adults with moderate ulcerative colitis (Mayo score 4 to 9, fecal calprotectin above 200 mcg/g), given AstraGin 50 mg twice daily or a maltodextrin placebo for 3 months. Lin CP, Yeh YT, Chiu MH, Pan TY, Shen YC, Journal of Biochemistry and Biotechnology 2023;6(2):138, doi 10.35841/aabb-6.2.138. That journal is not indexed in PubMed, so the paper has no PMID. Funded by Chung Shan Medical University; capsules donated by NuLiv Science. Note that the healthy-adult trial measured zonulin only and did not sample the microbiome; this pilot is the sole source of the microbiota figures quoted for AstraGin.
Adults with moderate ulcerative colitis, aged 25 to 70 (mean 43.4 years), 4 men and 5 women. Fourteen were screened, 9 were enrolled and 8 completed and were analysed: 5 on AstraGin and 3 on placebo.
Over 3 months, within the AstraGin arm fecal calprotectin fell 60.9% (p = 0.015), the lactulose to mannitol permeability ratio fell about 40% (p = 0.02) and myeloperoxidase activity fell 58% (p = 0.046); in the placebo arm calprotectin fell 10.9% and myeloperoxidase 7.0%, neither significant. Those p values compare each arm with its own baseline, not AstraGin with placebo. The one direct between-group comparison, L-arginine absorption, was 49.7% higher on AstraGin (p = 0.008). Faecalibacterium prausnitzii rose 420% and Bifidobacterium adolescentis rose 181% in the AstraGin group, reported as raw percentage changes with no significance test. Changes in IL-6, IL-17A, IL-1 beta, IL-10, microbiota alpha diversity and ghrelin were not significant, and the histological activity score fell 66.7% but did not reach significance (p = 0.078). With 5 people on AstraGin and 3 on placebo this is exploratory, and it was done in an inflammatory bowel condition rather than in healthy users.